Review Article
Impact of Ischemic Preconditioning on Outcome in Clinical Liver Surgery: A Systematic Review
Table 2
Summary of outcome in randomized controlled trials of ischemic preconditioning in orthotopic liver transplantation.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ALT, alanine aminotransferase; AR, acute rejection; AST, aspartate aminotransferase; Bili, bilirubin; DBD, donation after brain death; GS, graft survival; Histo, histology; HS, hospital stay; ICU, intensive care unit stay; INR, international normalized ratio; IOBL, intraoperative blood loss; IPC, ischemic preconditioning; IPF, initial poor function; LFT, liver function tests; NS, no statistically significant difference according to the author; PNF, primary nonfunction; PS, patient survival; PT, prothrombin time; PTA, prothrombin activity. 1IPF defined as INR >3.0 and/or total Bili >15 mg% in absence of biliary obstruction. 2IPF defined as minimal PTA <30% normal level and/or maximum Bili >15 mg/dL in absence of hemolysis or biliary obstruction. |